FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
GSK's Hibsago (bepirovirsen) received FDA approval for chronic hepatitis B in adults on nucleoside analogue therapy. Approval covers 1.7M U.S. patients, with 19% functional cure rate in trials. GSK estimates $926M sales by 2034. Competition includes Gilead's selgantolimod.
How this was made
The 30-second read
Why it matters
The approval expands GSK's infectious‑disease portfolio and may offset slower growth elsewhere.
Market read
First US approval of a hepatitis B functional‑cure therapy, creating a new revenue stream for GSK and influencing the antiviral sector.
What to watch
Pricing, reimbursement negotiations, and competition from Gilead's pipeline could limit upside.
Background
GSK licensed bepirovirsen from Ionis and completed Phase 3 B‑Well trials showing 19% functional cure versus 0% placebo.
Ticker impact
FDA approved Hibsago (bepirovirsen) for chronic hepatitis B, first US approval of the drug.
likely upward as investors price in future sales and functional‑cure potential.
Regulatory approval is a material catalyst; the drug targets ~1.7 M US patients and could generate hundreds of millions in sales.
Market effects
strengthens the biotech/antiviral segment and may spur competitor activity in hepatitis B treatments.
U.S. and Japan markets see new therapeutic option; European markets watch for rollout.
adds a functional‑cure candidate to the global hepatitis B pipeline, influencing investor sentiment across pharma.
Counterpoint
If sales uptake is slower than projected or safety concerns emerge, the stock could face disappointment.
Key entities
- companyGSK plc
British‑American pharmaceutical group developing Hibsago.
- companyIonis Pharmaceuticals
Licensor of the antisense oligonucleotide technology.
